ClinicalTrials.gg
CompletedNCT03180255Updated May 21, 2018

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

A Phase 2 interventional study of Dexamethasone phosphate and Placebo in Cataract, Anterior Chamber Inflammation and Pain, Postoperative, sponsored by Eyegate Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-05-21.

Sponsored by Eyegate Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2017, 9 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Enrollment
155th of 322
101 · median 100
Started
2017
with 13 others
Phase 2
18 of 456
none open now
Registered
233rd of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 155th largest by enrollment of the 322 interventional ones that give a count, is one of 14 that started in 2017, is one of 18 in phase 2, and was the 233rd registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

Phase 2b trial evaluating the safety and efficacy of EGP-437, versus placebo using the EyeGate® II Drug Delivery System (EGDS) in patients having undergone cataract surgery with implantation of a monofocal posterior chamber intraocular lens (IOL).

Read the detailed description

This will be a Phase 2b, double-masked, multi-site study, in which a total of up to 100 eyes of up to 100 subject will be enrolled at up to 8 clinical sites in the United States. The study has 2 different treatment arms consisting of the following iontophoresis treatment regimen:

Treatment Arm 1, up to 50 subjects will receive the following study treatment:

40 mg/ml dexamethasone phosphate solution delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA on Day 0 (immediately following cataract surgery), Day 1 (24 hours' post-cataract surgery), Day 4, and a potential Day 7 treatment that will be administered for subjects who have ≥11 AC cells per high-power field on slit lamp examination.

Treatment Arm 2, up to 50 subjects will receive the following study treatment:

100 mM sodium citrate buffer solution (placebo) delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA on Day 0 (immediately following cataract surgery), Day 1 (24 hours' post-cataract surgery), Day 4, and a potential Day 7 treatment that will be administered for subjects who have ≥11 AC cells per high-power field on slit lamp examination.

Subjects will come in for 6 visits over 28 days.

The primary efficacy endpoint (PEP) will evaluate 1) the proportion of subjects with an AC cell count of zero on Day 7 and 2) the proportion of subjects with a pain score of zero on Day 1.

03

Conditions studied

  • Cataract
  • Anterior Chamber Inflammation
  • Pain, Postoperative
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Undergoing unilateral cataract extraction and implantation of a monofocal IOL (at the time of enrollment)
  2. Age 18 to 85 years
  3. Receive, understand, and sign a copy of the written form (ICF)
  4. Are able to return for all study visits and willing to comply with all study-related instructions

Exclusion criteria

Exclusion Criteria:

  1. Are undergoing implantation of a multifocal and/or depth enhancing IOL
  2. Are undergoing or have just undergone cataract surgery on the study eye that is deemed complex or may require manipulation of the iris
  3. The study eye has a small pupil or iris requiring manipulation due to synechiae and/ Tamsulosin (Flomax®, Boehringer Ingelheim) use
  4. Have a Seidel positive wound following surgical procedure despite suture and/or ReSure® Sealant placement
  5. Have had ocular surgery of any kind in the study eye within 3 months prior to baseline visit (Day 0)
  6. Have undergone cataract surgery in the fellow eye within 4 weeks prior to baseline visit (Day 0) and still require post-operative medications in that fellow eye
  7. Are scheduled for surgery in the fellow eye within the study period
  8. Have anterior chamber inflammation as measured by slit lamp examination in the study eye at the baseline visit (Day 0) [Defined as anterior chamber (AC) cell and/or flare grade > 0]
  9. Have history of uveitis or inflammatory disease in the study eye
  10. Requires simultaneous supplemental surgery, such as glaucoma procedures or vitrectomy, in the study eye
  11. Have used any topical ocular medication in either eye, other than tear substitute for dry eye, within the past 2 weeks prior to baseline visit (Day 0)
  12. Have used topical or nonsteroidal anti-inflammatory drug (NSAID) treatment in either eye \< 48 hours prior to the baseline visit (Day 0) (excluding the use of topical NSAIDs, pre-operatively on Day 0 and administered at the clinic site under the investigator's oversight)
  13. Have IOP ≥ 25 mmHg at baseline, a history of glaucoma, and/or require ocular anti-hypertensive medications
  14. Are known corticosteroid IOP responder in study eye
  15. Have received systemic administration of corticosteroid and/or within the past 14 days prior to baseline visit (Day 0)
  16. Have received intravitreal, sub-Tenon, or any periocular corticosteroid treatment in either eye within the past 6 months prior to baseline visit (Day 0)
  17. Have open wounds/skin disease on the forehead area where the iontophoresis return electrode will be applied
  18. Have lesions of the eyelids or the ocular surface impeding the application of the iontophoresis applicator
  19. Have blepharospasm, blepharophimosis, or other eyelid anatomic variations precluding placement of the iontophoresis applicator
  20. Have known allergy to dexamethasone or dexamethasone phosphate or any medication to be used in this study
  21. Have history or diagnosis of ocular herpes, corneal lesion of suspected herpetic origin that could be worsened with steroid use
  22. Have optic neuritis of any origin
  23. Have clinically suspected or confirmed central nervous system or ocular lymphoma
  24. Have active hyphema, pars planitis, choroiditis, toxoplasmosis scar, vitreous hemorrhage, and/or macular edema (CSME) that would compromise visual acuity recovery
  25. Have severe/serious ocular pathology or medical condition which may preclude study completion
  26. Have pacemaker and/or any other electrical sensitive support system
  27. Are pregnant or lactating female, or female of childbearing age and using inadequate method
  28. Have participated in another device or drug study within 30 days of baseline visit (Day 0) (other clinical trial participation while participating in EGP-437-009 would be prohibited per protocol)
  29. Have previously participated in a study with EGP-437
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    EGP-437

    40 mg/ml dexamethasone phosphate solution delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA

    Combination Product: Dexamethasone phosphate

  • Placebo comparator
    Placebo

    100 mM sodium citrate buffer solution (placebo) delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA

    Other: Placebo

Interventions

  • Combination productDexamethasone phosphate

    Ocular iontophoretic delivery of a steroid

  • OtherPlacebo

    Ocular iontophoretic delivery of a placebo

    Also known as: Sodium Citrate Buffer

06

What researchers measure

Primary outcomes

  1. AC cell count = 0

    The proportion of subjects with an AC cell count of zero on Day 7

    Time frame: 7 days' following first study treatment

  2. Pain score = 0

    The proportion of subjects with a pain score of zero on Day 1

    Time frame: 1 day post-surgery and following first study treatment

07

Study locations

1 site
  • Site 901
    Jacksonville, Florida 32204, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Nov 2017, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2017
First posted
Jun 8, 2017
StartActual
Jul 26, 2017
Primary completionActual
Nov 7, 2017
CompletionActual
Nov 27, 2017
Last update
May 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03180255
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jun 8, 2017
Start date
Jul 26, 2017
Primary completion
Nov 7, 2017
Completion
Nov 27, 2017
Last update
May 21, 2018

Study contacts

Lisa Brandano, BS
study director · VP, Clinical Operations

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion